scholarly journals Association between lysyl oxidase and fibrotic focus in relation with inflammation in breast cancer

2017 ◽  
Author(s):  
Young Jeong ◽  
Sung Park ◽  
Sung Mun ◽  
Sang Kwak ◽  
Sun‑Jae Lee ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lysyl Oxidase ◽  
Fibrotic Focus

Lysyl Oxidase is essential for hypoxia-induced metastasis in breast cancer

2006 ◽  
Vol 66 (S 01) ◽  
Author(s):  
JT Erler ◽  
N Dornhöfer ◽  
S Jeffrey ◽  
A Giaccia
Keyword(s):  
Breast Cancer ◽  
Lysyl Oxidase

scholarly journals LOXL2 Inhibitors and Breast Cancer Progression

Antioxidants ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 312
Author(s):  
Sandra Ferreira ◽  
Nuno Saraiva ◽  
Patrícia Rijo ◽  
Ana S. Fernandes
Keyword(s):  
Breast Cancer ◽  
Cancer Progression ◽  
Cancer Biology ◽  
Breast Cancer Cells ◽  
Lysyl Oxidase ◽  
Breast Cancer Progression ◽  
Special Focus ◽  
Amine Oxidases ◽  
Cross Link ◽  
Promising Strategy

LOX (lysyl oxidase) and lysyl oxidase like-1–4 (LOXL 1–4) are amine oxidases, which catalyze cross-linking reactions of elastin and collagen in the connective tissue. These amine oxidases also allow the cross-link of collagen and elastin in the extracellular matrix of tumors, facilitating the process of cell migration and the formation of metastases. LOXL2 is of particular interest in cancer biology as it is highly expressed in some tumors. This protein also promotes oncogenic transformation and affects the proliferation of breast cancer cells. LOX and LOXL2 inhibition have thus been suggested as a promising strategy to prevent metastasis and invasion of breast cancer. BAPN (β-aminopropionitrile) was the first compound described as a LOX inhibitor and was obtained from a natural source. However, novel synthetic compounds that act as LOX/LOXL2 selective inhibitors or as dual LOX/LOX-L inhibitors have been recently developed. In this review, we describe LOX enzymes and their role in promoting cancer development and metastases, with a special focus on LOXL2 and breast cancer progression. Moreover, the recent advances in the development of LOXL2 inhibitors are also addressed. Overall, this work contextualizes and explores the importance of LOXL2 inhibition as a promising novel complementary and effective therapeutic approach for breast cancer treatment.

Hypoxia/reoxygenation: A dynamic regulator of lysyl oxidase-facilitated breast cancer migration

2008 ◽  
Vol 103 (5) ◽  
pp. 1369-1378 ◽  
Author(s):  
Lynne-Marie Postovit ◽  
Daniel E. Abbott ◽  
Stacey L. Payne ◽  
William W. Wheaton ◽  
Naira V. Margaryan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lysyl Oxidase ◽  
Cancer Migration ◽  
Hypoxia Reoxygenation

scholarly journals ATP7A delivers copper to the lysyl oxidase family of enzymes and promotes tumorigenesis and metastasis

2019 ◽  
Vol 116 (14) ◽  
pp. 6836-6841 ◽  
Author(s):  
Vinit Shanbhag ◽  
Kimberly Jasmer-McDonald ◽  
Sha Zhu ◽  
Adam L. Martin ◽  
Nikita Gudekar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lysyl Oxidase ◽  
Meta Analysis ◽  
Myeloid Cell ◽  
Breast Cancer Patients ◽  
Orthotopic Mouse Model ◽  
Copper Transporter ◽  
Cell Recruitment ◽  
Lung Carcinoma Cells ◽  
Lewis Lung Carcinoma Cells

Lysyl oxidase (LOX) and LOX-like (LOXL) proteins are copper-dependent metalloenzymes with well-documented roles in tumor metastasis and fibrotic diseases. The mechanism by which copper is delivered to these enzymes is poorly understood. In this study, we demonstrate that the copper transporter ATP7A is necessary for the activity of LOX and LOXL enzymes. Silencing of ATP7A inhibited LOX activity in the 4T1 mammary carcinoma cell line, resulting in a loss of LOX-dependent mechanisms of metastasis, including the phosphorylation of focal adhesion kinase and myeloid cell recruitment to the lungs, in an orthotopic mouse model of breast cancer. ATP7A silencing was also found to attenuate LOX activity and metastasis of Lewis lung carcinoma cells in mice. Meta-analysis of breast cancer patients found that high ATP7A expression was significantly correlated with reduced survival. Taken together, these results identify ATP7A as a therapeutic target for blocking LOX- and LOXL-dependent malignancies.

Lysyl Oxidase 473 G>A Polymorphism and Breast Cancer Susceptibility in Chinese Han Population

2011 ◽  
Vol 30 (2) ◽  
pp. 111-116 ◽  
Author(s):  
Jinghua Ren ◽  
Xiaoling Wu ◽  
Wenshan He ◽  
Jun Shao ◽  
Bo Cheng ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Susceptibility ◽  
Lysyl Oxidase ◽  
Breast Cancer Susceptibility ◽  
Chinese Han Population ◽  
Chinese Han ◽  
Han Population

scholarly journals The Lysyl Oxidase Pro-peptide Attenuates Fibronectin-mediated Activation of Focal Adhesion Kinase and p130Casin Breast Cancer Cells

2008 ◽  
Vol 284 (3) ◽  
pp. 1385-1393 ◽  
Author(s):  
Yingshe Zhao ◽  
Chengyin Min ◽  
Siddharth R. Vora ◽  
Philip C. Trackman ◽  
Gail E. Sonenshein ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Focal Adhesion Kinase ◽  
Cancer Cells ◽  
Focal Adhesion ◽  
Breast Cancer Cells ◽  
Lysyl Oxidase
Sign in / Sign up

Export Citation Format

Share Document